Millendo Therapeutics
closedAtterocor focuses on research and development of therapeutics for adrenal disease.
Employees
Enterprise value
$120—180m
Company register number
497575621
Recent deals
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Merger | ||
| Total Funding | 000k | ||
NEA(exited)
Adams Street Partners(exited)
Frazier Healthcare Partners(exited)
Altitude Life Science Ventures(exited)
Roche Venture Fund(exited)
Longwood Fund(exited)
5AM Ventures(exited)
Renaissance Venture Capital Fund(exited)
Osage University Partners(exited)
Ann Arbor Spark(exited)
Turenne Capital(exited)
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Millendo Therapeutics
Edit
ACQUISITION by AstraZeneca Mar 2024
ACQUISITION by Millendo Therapeutics Aug 2018
exited